- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108601
Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity
April 20, 2010 updated by: McGill University Health Centre/Research Institute of the McGill University Health Centre
Transtympanic Administration of Lactate: An Innovative Otoprotection for Patients Receiving Cisplatin or Carboplatin Chemotherapy
Cisplatin and carboplatin induce ototoxicity manifested as sensorineural hearing loss, tinnitus, and/or vestibular disturbances.
Ototoxicity is induced via damage to inner ear structures by reactive oxygen species.
Previous animal studies demonstrated that transtympanic injection of Ringer's Lactate (RL) provided near complete otoprotective effect against cisplatin.
The purpose of this study is to determine if transtympanic administration of Ringer's Lactate via a pressure equalising (PE) tube in patients undergoing platinum based chemotherapy treatment will prevent tinnitus, vestibular dysfunction and hearing loss especially at high frequencies.
Pre- and post- chemotherapy treatment audiometry will be measured and statistically analysed for significance.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Victoria Akinpelu
- Phone Number: 22249 514-412-4400
- Email: victoriakinpelu@gmail.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A1
- Recruiting
- Montreal General Hospital
-
Contact:
- Victoria Akinpelu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients over the age of 14
- Patients undergoing platinum based chemotherapy
- Patients who agree to participate in the study
Exclusion Criteria:
- Patients unable to provide consent
- Patients with head and neck cancer
- Patients undergoing radiation of the head and neck
- Patients who develop a tympanic perforation
- Patients with persistent otorrhea
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Ringer's Lactate
Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
|
For each patient, only one ear will receive the Ringer's Lactate solution.
The other ear will act as a control.
To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment.
The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Audiogram
Time Frame: Before and after chemotherapy treatment
|
Pre-, mid-(if available) and post-chemotherapy treatment audiograms will be compared to determine changes in hearing from baseline and between ears.
Hearing will also be assessed every six months after chemotherapy treatment for up to four years to determine possible long-term effects.
|
Before and after chemotherapy treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Otoacoustic Emissions
Time Frame: Before and after chemotherapy treatment
|
Distortion Product Otoacoustic Emissions will also be measured before and after chemotherapy treatment and compared to determine significance.
|
Before and after chemotherapy treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sam J Daniel, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (ANTICIPATED)
April 1, 2011
Study Registration Dates
First Submitted
April 1, 2010
First Submitted That Met QC Criteria
April 20, 2010
First Posted (ESTIMATE)
April 22, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
April 22, 2010
Last Update Submitted That Met QC Criteria
April 20, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Wounds and Injuries
- Otorhinolaryngologic Diseases
- Ear Diseases
- Sensation Disorders
- Hearing Disorders
- Drug-Related Side Effects and Adverse Reactions
- Radiation Injuries
- Hearing Loss
- Ototoxicity
- Deafness
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Ciprofloxacin
Other Study ID Numbers
- GEN-07-033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hearing Loss
-
University of California, San FranciscoPatient-Centered Outcomes Research InstituteRecruitingHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Noise-Induced | Hearing Loss, Unilateral | Hearing Loss, Mixed | Hearing Disorders in ChildrenUnited States
-
Oticon MedicalRecruitingEar Diseases | Hearing Loss, Conductive | Hearing Loss Mixed | Hearing Disability | Conductive Hearing Loss | Conductive Hearing Loss, Bilateral | Conductive Hearing Loss, UnilateralUnited Kingdom
-
MED-EL Elektromedizinische Geräte GesmbHCompletedHearing Loss | Hearing Loss, Sensorineural | Hearing Loss, Bilateral | Hearing Loss, Conductive | Hearing Loss, Unilateral | Hearing Loss, MixedAustria, Germany, United Kingdom
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Oticon MedicalCompletedConductive Hearing Loss | Conductive and Sensori-neural Hearing Loss in the Same Ear | Unilateral, Profound Sensori-neural Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Frequency TherapeuticsCompletedHearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing LossUnited States
-
Otologic Pharmaceutics, Inc.CompletedHearing Loss | Sensorineural Hearing Loss | Noise-Induced Hearing LossUnited States
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
Clinical Trials on Ringer's Lactate (0.03% Ciprofloxacin)
-
University of CalgaryNot yet recruitingPost-ERCP Acute Pancreatitis
-
Ottawa Hospital Research InstituteCompleted
-
Paraskevi MatsotaCompleted
-
Ottawa Hospital Research InstituteCompleted
-
University of Sao PauloCompletedHip Replacement ArthroplastyBrazil
-
Alexandria UniversityCompletedNausea and Vomiting, PostoperativeEgypt
-
Innogene Kalbiotech Pte. LtdCompleted
-
MetroHealth Medical CenterCompletedFetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and DeliveryUnited States
-
St. Boniface HospitalUniversity of ManitobaUnknown
-
Innogene Kalbiotech Pte. LtdCompletedLow Cardiac OutputIndonesia